
Feature|Articles|August 28, 2026
Preventing Batch Loss: The Growing Role of Preventive and Predictive Maintenance
Author(s)Israel Ortiz
With biopharma batch failures averaging every 40 weeks, predictive maintenance and connected monitoring are becoming critical quality levers.
Advertisement
Advertisement
Pharmaceutical manufacturers operate under some of the strictest quality requirements in any industry. Even small deviations in a facility’s environmental conditions can compromise product stability and risk batch losses that can cost manufacturers millions of dollars in lost product, investigations, and production delays. Despite improvements in manufacturing technology, batch failures still occur due to contamination, operator error, and equipment failure. On average, biopharmaceutical manufacturers experience a failure every 40 weeks.
Related to this article

Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.

Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.

Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.

Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior immunity.

Phagenyx’s Chad Hoskins on why AHA/ASA guideline inclusion gives stroke teams a basis to use PES earlier — and what the evidence shows.

Pfizer’s talazoparib-enzalutamide combination moves to earlier line in prostate cancer, with eligibility tied to genetic testing and immature survival data.

Bristol Myers Squibb discloses results from it's Phase I Breakfree-2 trial of CAR-T therapy zola-cel for multiple sclerosis.
Advertisement
Advertisement

